|
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis |
Benucci M, Stam WB, Gilloteau I, Sennfalt K, Leclerc A, Maetzel A, Lucioni C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Benucci M, Stam WB, Gilloteau I, Sennfalt K, Leclerc A, Maetzel A, Lucioni C. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Clinical and Experimental Rheumatology 2013; 31(4): 575-583 Indexing Status Subject indexing assigned by NLM MeSH Abatacept; Adult; Antibodies, Monoclonal /administration & Antirheumatic Agents /administration & Arthritis, Rheumatoid /drug therapy /economics; Double-Blind Method; Drug Costs; Drug Resistance; Drug Therapy, Combination; Female; Health Care Costs; Humans; Immunoconjugates /administration & Infliximab; Italy; Male; Methotrexate /administration & Middle Aged; Placebos; Remission Induction; dosage /adverse effects /economics; dosage /adverse effects /economics; dosage /adverse effects /economics; dosage /adverse effects /economics AccessionNumber 22013044590 Date bibliographic record published 31/10/2013 |
|
|
|